65 results about "Glycated albumin" patented technology

A home test for measuring glycated albumin levels in saliva. The saliva sample is collected at home using a standardized saliva collection kit and mailed to a testing laboratory that performs the test and reports the result directly back to the customer via the internet. The home test can be used to monitor glucose control in diabetics and in healthy individuals. It may also be used as a diagnostic aid in identifying individuals with diabetes, or who are at risk of developing diabetes.

A rapid immunochromatographic assay system is provided for measuring the amount of glycated albumin in a blood sample relative to the total level of albumin in the sample. The assay system is comprised of a disposable cassette that contains the test strips and testing reagents, and a measurement device that automatically reads, calculates and displays the test results over a period of time. The test cassette contains two test strips that are used to measure glycated albumin and total albumin respectively. The strips are contiguous beneath the single sample application well so that the same sample is tested simultaneously by both test strips. Part of the sample will migrate thru the glycated albumin test strip where it will react with the glycated albumin test reagents to yield a glycated albumin result, while part of the sample will migrate thru the total albumin test strip where it will react with the total albumin test reagents to yield a total albumin result. The test cassette is placed within a measuring device such as a reflectance spectrometer or fluorometer, that reads, calculates and expresses the result as the percentage of glycated albumin relative to total albumin in the sample. The results of successive testing that are performed over a period of time are stored in the instrument's memory and displayed in a numerical or graphical format so that the individual's glycated albumin levels can be monitored over time.

Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) siabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.

This invention describes a point-of-care or home use device for measuring the ratio of glycated albumin to total albumin in saliva and other body fluids. Diabetics and prediabetics may have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. Saliva albumin is derived from plasma albumin and therefore contains glycated and non-glycated albumin fractions that can be measured. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period.The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

This invention describes a rapid immunochromatographic assay for measuring the ratio of glycated albumin to total albumin in saliva. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. Saliva albumin is derived from plasma albumin and therefore contains glycated and non-glycated albumin fractions that can be measured. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period.The test is performed using a disposable strip that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

The invention provides a human serum glycated albumin assay kit which comprises a reagent 1 and a reagent 2, wherein the reagent 1 comprises the following components: 20-200mmol / L of buffer solution, 5-50KU / L of protease co-expression vector, 10-50KU / L of peroxisome, 2-20mmol / L of 4-amino antipyrine, 0.01-1% of preservative and 0.01-1% of stabilizer, and the protease co-expression vector is obtained by cloning a protease gene and an ascorbic acid oxidase gene onto a same vector for performing co-expression; and the reagent 2 comprises the following components: 20-200mmol / L of buffer solution, 5-50U / mL of fructose lysine enzyme, 1-10mmol / L of N, N-bis(4-sulfobutyl ether)-3-methylaniline, 0.01-1% of preservative and 0.01-1% of stabilizer. The kit can remove the interferences of globulin and ascorbic acid in human serum and has good stability and low cost.

Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

This invention describes a rapid assay for measuring the ratio of glycated albumin to total albumin in blood. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. The ratio of glycated albumin to total albumin in blood will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period.The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

An albumin denaturing agent for digesting an albumin by a protease efficiently is provided. The albumin denaturing agent contains quaternary ammonium having a hydrocarbon group with a carbon number of 12 or more, or a salt of the quaternary ammonium. The albumin in a sample is digested by the protease in the presence of the albumin denaturing agent, a glycated part of the thus obtained albumin digestion product and a FAOD effect a reaction, and a redox reaction between the glycated part and the FAOD is measured, thereby determining a ratio (GA (%)) of the glycated albumin of the glycated albumin with respect to the albumin.

Disclosed herein is a point-of-care or home use device for measuring the ratio of glycated albumin to total albumin in saliva and other body fluids. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

The invention discloses a method for detecting serum glycated albumin and a special candidate reference substance thereof. The present invention provides a method using an isotope dilution liquid chromatography tandem mass spectrometry method for the determination of glycated albumin content in a sample to be detected. The method comprises the following steps: 1) preparing a standard solution, and separating and purifying the albumin in a sample to be detected; 2) preparing a working standard solution and a working sample to be detected; 3) respectively detecting the working standard solution and the working sample to be detected by using a liquid chromatography tandem mass spectrometer to obtain the glycated albumin content in the sample to be detected. The experiment of the invention has proved that based on a JSCC recommendation method, a candidate reference method for accurate determination of glycated albumin is established by using the liquid chromatography tandem triple quadrupole. On this basis, a GA candidate reference substance for freezing and mixing human serum matrix is developed, and the invention is expected to be further used for the chamber evaluation and validation of the GA project.

The invention provides a method for preparing fructose lysine enzyme and a glycated albumin detection kit, wherein the glycated albumin detection kit is prepared by utilizing the fructose lysine enzyme that is prepared by adopting the method. The method comprises the operation steps as follows: strains are screened so as to obtain 11 to 82 aspergillus strains of the high-activity fructose lysine enzyme; the 11 to 82 aspergillus strains are cultivated, and mycelia are collected; the mycelia are suspended in buffer solution, and then are processed through cell disruption and centrifugation, and supernatant fluid is collected; the supernatant fluid is processed through fractional precipitation by adopting ammonium sulfate solution, and deposits are collected so as to obtain crude extracts; the crude extracts are processed through hydrophobic chromatography, and eluant is collected; in addition, the collected eluant is processed through affinity chromatography, and then eluant is collected, that is, fructose lysine enzyme solution is obtained. The method has the advantages as follows: the preparation steps are simple, and the obtained fructose lysine enzyme achieves high purity, high activity and high reaction specificity.

The invention discloses a binary-channel test card for detecting a human glycated albumin. The binary-channel test card is characterized in that a sample pad, a bonding pad, a cellulose nitrate membrane and a water absorption pad are orderly adhered to a PVC backing; special monoclonal antibodies and aptamers of a human glycated albumin and an albumin are used as detection reagents and are used for detecting content of the human glycated albumin and the total albumins. The binary-channel test card can detect a ratio of the glycated albumin to the total albumins in a human biological sample such as a blood sample and a saliva sample, utilizes saliva replacing blood to carry out non-invasive detection, and prevents inconvenience and danger of blood sampling. The binary-channel test card is convenient for fast, accurate and simple control and monitoring of a blood sugar level.

The present invention provides a method for long-term stabilization of inositol dehydrogenase, ketoamine oxidase and sphingomyelinase in liquid. The method is used to prepare an enzymatic biochemicalkit for determining inositol, glycated albumin and small and dense low density lipoprotein cholesterol for a purpose of enabling the enzymatic biochemical kit to have a shelf life of 12 months or more. The method is characterized in that a composition of 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether is added to a reagent solution for preserving enzymes, and concentrations of the 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether are preferably 0.008-0.012 w / V% and 0.1-0.2 w / V%, respectively.